Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG4 Pneumococcal Vaccine in Healthy Infants
NCT06524414Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2024
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of PG4 in pneumococcal disease, sponsored by Pfizer. Started Jul 2024; status: active, not recruiting.
02
Drugs
PG4
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06524414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524414.